Historical Valuation
Crinetics Pharmaceuticals Inc (CRNX) is now in the Fair zone, suggesting that its current forward PS ratio of 129.59 is considered Fairly compared with the five-year average of -8.14. The fair price of Crinetics Pharmaceuticals Inc (CRNX) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：53.34
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Crinetics Pharmaceuticals Inc (CRNX) has a current Price-to-Book (P/B) ratio of 4.12. Compared to its 3-year average P/B ratio of 3.89 , the current P/B ratio is approximately 5.92% higher. Relative to its 5-year average P/B ratio of 3.70, the current P/B ratio is about 11.37% higher. Crinetics Pharmaceuticals Inc (CRNX) has a Forward Free Cash Flow (FCF) yield of approximately -7.98%. Compared to its 3-year average FCF yield of -8.49%, the current FCF yield is approximately -5.98% lower. Relative to its 5-year average FCF yield of -8.94% , the current FCF yield is about -10.74% lower.
P/B
Median3y
3.89
Median5y
3.70
FCF Yield
Median3y
-8.49
Median5y
-8.94
Competitors Valuation Multiple
AI Analysis for CRNX
The average P/S ratio for CRNX competitors is 25.20, providing a benchmark for relative valuation. Crinetics Pharmaceuticals Inc Corp (CRNX.O) exhibits a P/S ratio of 129.59, which is 414.27% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for CRNX
1Y
3Y
5Y
Market capitalization of CRNX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of CRNX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is CRNX currently overvalued or undervalued?
Crinetics Pharmaceuticals Inc (CRNX) is now in the Fair zone, suggesting that its current forward PS ratio of 129.59 is considered Fairly compared with the five-year average of -8.14. The fair price of Crinetics Pharmaceuticals Inc (CRNX) is between to according to relative valuation methord.
What is Crinetics Pharmaceuticals Inc (CRNX) fair value?
CRNX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Crinetics Pharmaceuticals Inc (CRNX) is between to according to relative valuation methord.
How does CRNX's valuation metrics compare to the industry average?
The average P/S ratio for CRNX's competitors is 25.20, providing a benchmark for relative valuation. Crinetics Pharmaceuticals Inc Corp (CRNX) exhibits a P/S ratio of 129.59, which is 414.27% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Crinetics Pharmaceuticals Inc (CRNX) as of Jan 09 2026?
As of Jan 09 2026, Crinetics Pharmaceuticals Inc (CRNX) has a P/B ratio of 4.12. This indicates that the market values CRNX at 4.12 times its book value.
What is the current FCF Yield for Crinetics Pharmaceuticals Inc (CRNX) as of Jan 09 2026?
As of Jan 09 2026, Crinetics Pharmaceuticals Inc (CRNX) has a FCF Yield of -7.98%. This means that for every dollar of Crinetics Pharmaceuticals Inc’s market capitalization, the company generates -7.98 cents in free cash flow.
What is the current Forward P/E ratio for Crinetics Pharmaceuticals Inc (CRNX) as of Jan 09 2026?
As of Jan 09 2026, Crinetics Pharmaceuticals Inc (CRNX) has a Forward P/E ratio of -8.36. This means the market is willing to pay $-8.36 for every dollar of Crinetics Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Crinetics Pharmaceuticals Inc (CRNX) as of Jan 09 2026?
As of Jan 09 2026, Crinetics Pharmaceuticals Inc (CRNX) has a Forward P/S ratio of 129.59. This means the market is valuing CRNX at $129.59 for every dollar of expected revenue over the next 12 months.